Key impacts on the market access and payer environment are beginning to unfold from policies enacted in 2023 and new policies enacting in 2024. To gather insights into the latest trends, Trinity Life Sciences conducted interviews with key stakeholders across various pricing and market access landscapes. Trinity is closely monitoring the evolving global advanced therapeutics market environment to determine implications for payers and manufacturers and help them prepare for the year ahead.
This retrospective analysis of medical chart data was performed to compare severity and treatment of gout in patients with or without a history of kidney transplantation (KT). Authors Lauren Radeck, Clive M. Mendonca, Isabel Lang, Jeffrey Kent, Brian Lamoreaux, Richard J. Johnson Journal American Society of Nephrology Meeting, October 2018 View publication…
Trinity has worked with over a third of companies with cell and gene therapies (CGTs) on market or in Phase 3 clinical trials. Our work has supported business development, launch planning, evidence generation (HEOR, etc.), market access, pricing, and other critical commercial activities to support the development and launch of these therapies. As such, we have seen CGTs morph from a small niche into possibly the most exciting market in pharma. 2019 is poised to be an inflection point for…
Hypoactive sexual desire disorder (HSDD) is the most prevalent form of female sexual dysfunction (FSD) in the United States and is characterized by a decrease or lack of sexual desire accompanied by distress. Despite the relatively high prevalence of HSDD in US women 18-44 years of age (∼10%), there is a limited understanding of the condition among physicians. Authors Sharon Parish, Zainab Shahpurwala, Amod Athavale, Rahul Ravindranath, Nandini Hadker, and Michelle Lim-Watson Journal ISSWSH / ISSM Joint Meeting, March 2019…
The annual Trinity Drug Index provides a comprehensive evaluation of the performance of drugs by therapeutic value, commercial performance and R&D complexity. By submitting this form, creating an account, and/or using our website (or using our Services) you agree to our Privacy Policy. Information provided by you is stored in our database and may be used for sending you additional information about Trinity (including Trinity’s partners and affiliates) and our products and services. Such information may be transferred for this purpose…
By Curt Staab, TGaS® Advisors, a division of Trinity Executive Summary TGaS® Advisors’ Emerging Life Sciences Network (elsN) has gathered advice and lessons learned from a broad-based CCO peer network to create this guide, the first in a series designed to help CCOs manage day-to-day and for the long-term. In this White Paper, we provide an overview of a CCO’s responsibilities, resources and expectations. Future issues will offer advice from peers and experts on launch planning and hiring. To learn more,…
Age and frailty are risk factors for overactive bladder (OAB), but less is known about their association with OAB burden. Authors Amod Athavale, Marissa Suh, Ali Haber, Jillian Godfrey Scaife, Nandini Hadker, Katherine Gooch Journal AGS Annual Meeting, May 2019 View publication…
Genitourinary syndrome of menopause (GSM) is a chronic, progressive condition affecting up to 60% of post-menopausal women in the United States. Dyspareunia, or pain with sexual intercourse, has been recognized as one of GSM’s most bothersome symptoms. Despite high prevalence and availability of treatments, many women are not adequately managed, and unmet need remains. The objective of this systematic literature review was to characterize the unmet need. Authors S.S. Faubion, S.S. Karkare, K.R. Hennegan, N. Hadker, B.R. Robinson, M.Z. Lim-Watson…
Claims-based prediction models commonly use dichotomous indicator variables (e.g., presence/absence of disease) or count variables (e.g., frequency of claims) as predictors. The research objective was to compare the predictive ability of this standard model with other models that account for the sequence of events. The models were applied in the context of predicting hypoparathyroidism diagnosis among Medicare beneficiaries. Authors Site Li, Bingqing Yu, Xinyi Wang, Guangyan Yu, Diptanshu Singh, Gavin Miyasato, Masanao Yajima Journal ISPOR Meeting, May 2019 View publication…
The objective is to understand the unmet needs related to the diagnosis and management of patients with hypoactive sexual desire disorder (HSDD). Authors Sharon Parish, Zainab Shahpurwala, Rahul Ravindranath, Amod Athavale, Nandini Hadker, and Michelle Lim-Watson Journal ISPOR Meeting, May 2019 View publication…
The purpose of this study was to systematically assess rates of treatment-emergent hypophosphatemia among IDI formulations used in IDA. Authors Lim-Watson M, Libre M, Karkare S, Alkhateeb Z, Hadker N, Bajic-Lucas A, Dahl N, Strauss W, Glaspy J Journal ISPOR Meeting, May 2019 View publication…
By signing up, you are agreeing to our Privacy Policy.
By submitting this form, creating an account, and/or using our website (or using our Services) you agree to our Privacy Policy. Information provided by you is stored in our database and may be used for sending you additional information about Trinity (including Trinity’s partners and affiliates) and our products and services. Such information may be transferred for this purpose to Trinity and affiliates in other countries. If you would like to opt out in the future, please email _compliance@trinitylifesciences.com.
